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Abstract
Background: Osteoporosis is a serious health problem that worsens the quality of life and the survival rate of
individuals with this disease on account the osteoporotic fractures. Studies have long focused on women, and its
presence in men has been underestimated. While many studies conducted in different countries mainly assess
health-related quality of life and identify fracture risks factors in women, few data are available on a Spanish male
population.
Methods/Design: Observational study.
Study population: Men ≥ 40 years of age with/without diagnosed osteoporosis and with/without osteoporotic
fracture included by their family doctor.
Measurements: The relationship between customary clinical risk factors for osteoporotic fracture and health-
related quality of life in a Spanish male population. A telephone questionnaire on health-related quality of life is
made.
Statistical analysis: The association between qualitative variables will be assessed by the Chi-square test. The
distribution of quantitative variables by Student’s t-test. If the conditions for using this test are not met, the non-
parametric Mann-Whitney’s U test will be used.
The validation of the results obtained by the FRAX™ tool will be performed by way of the Hosmer-Lemeshow test
and by calculating the area under the Receiver Operating Characteristic (ROC) curve (AUC). All tests will be
performed with a confidence intervals set at 95%.
Discussion: The applicability and usefulness of Health-related quality of life (HRQOL) studies are well documented
in many countries. These studies allow implementing cost-effective measures in cases of a given disease and
reducing the costly consequences derived therefrom. This study attempts to provide objective data on how quality
of life is affected by the clinical aspects involved in osteoporosis in a Spanish male population and can be useful
as well in cost utility analyses conducted by health authorities.
The sample selected is not based on a high fracture risk group. Rather, it is composed of men in the general
population, and accordingly comparisons should not lead to erroneous interpretations.
A possible bias correction will be ensured by checking reported fractures against healthcare reports and X-rays, or
by consulting health care centers as applicable.
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Epidemiology
The study of osteoporosis (OP) has long focused on
women, and its presence in men has been underesti-
mated despite the existence of important morbidity and
mortality data.
Prevalence data in Spain reflect densitometric OP per-
centages of 6% in men aged between 60 and 69 years,
11.3% in the lumbar spine of men aged between 70-79
years, and 2.6% in the femoral neck of older men [1,2].
Epidemiological data of vertebral fractures in a Span-
ish male population are difficult to calculate because
30% of these are symptomatic; however, a prevalence
rate of 572 per 100,000 population was published by the
EVOS study [3]. Hip fractures are the easiest to docu-
ment because most of them require hospitalization for
treatment. Data from the Ministry of Health and Con-
sumption [4] reports an annual incidence rate of these
fractures among men of 270 cases per 100,000 people
older than 64 years. Also to be emphasized is that the
mortality rate after vertebral fracture seems to be higher
in men as compared to women [5] in the older age
groups.
Health-related quality of life (HRQOL)
Decreased HRQOL in women with osteoporotic fracture
is well documented, as are the economic repercussions
involved (the occurrence of fractures implies a loss of
0.3 HRQOL points on the EQ-5D health state classifica-
tion [1]). Also, this worsening persists for years after
sustaining the fracture [2]. In contrast, little information
is available in the male population. The purpose of this
study is to objectively measure the degree of HRQOL
worsening in men by validated questionnaires, complete
with clinical aspects related to osteoporosis and bone
density scan results (DXA).
OP-related HRQOL distinguishes between OP patients
with or without fracture. These two categories worsen
the patient’s quality of life on account of fear to sustain
new fall-related fractures, fracture-related pain, resulting
vertebral deformity, respiratory compromise, limited hip
mobility due to some fractures, and death of a relevant
number of patients within one year after hip fracture
surgery [6].
Patients may be evaluated by generic HRQOL instru-
ments such as the SF-36 [7], the EuroQol [8], or the
COOP/WONCA charts [9]. The latter, however, may
lack sensitivity to detect significant clinical changes
within the scope of OP, such as morbidity caused by
vertebral fractures and resulting pain or inability,
impaired body image, possible isolation, or mood altera-
tions. Accordingly, specific questionnaires to evaluate
OP have been created, such as the QUALEFFO (Quality
of Life Questionnaire of the European Foundation for
Osteoporosis) [10] or the ECOS-16 [11] questionnaires.
A possible drawback of these specific questionnaires is
the impossibility of making comparisons between differ-
ent populations.
The EuroQol-5D (EQ-5D) is a generic HRQOL instru-
ment that consists of 2 parts: one describes the different
health dimensions and the other is a Visual Analogue
Scale. The items assessed include mobility, self-care,
daily activities, pain, and anxiety/depression. Each
dimension is divided into 3 degrees of severity: none,
moderate and severe (scored 1, 2 and 3, respectively).
The order of dimensions must be the same at all times.
ECOS-16 is an OP-specific questionnaire validated in
S p a i n ,o b t a i n e df r o mt h eg e n e r i cS F - 3 6a n dt h eQ U A -
LEFFO questionnaires. It is a shorter questionnaire (16
items) and thus proves useful in the daily medical prac-
tice. The health state is divided into 4 dimensions: phy-
sical function (5 items), pain (5 items), fear of illness (2
items), and psychosocial function (4 items). Each dimen-
sion is divided into 5 degrees of severity, varying from 1
(best health state) to 5 (worst health state).
Both EQ-5D and ECOS-16 are readily administered
questionnaires (< 5.0 minutes and 12.3 minutes, respec-
tively) and accordingly these were selected for HRQOL
evaluation in our study. Indeed, time is a major draw-
back when assessing the biopsychosocial context of our
patients and, on the other hand, their briefness helps
keep the patient’s and the health care provider’si n t e r e s t
awake.
OP and osteoporotic risk factors for fracture in men
While many studies conducted in different countries
identify fracture-related risk factors [12], few data are
available on the Spanish male population.
In the year 2004, Kanis et al [13] identified low BMI,
smoking, family history of fragility fracture and gluco-
corticoid intake as risk factors for fracture in men.
Other risk factors cited in the literature [14,15] include
old age (> 70 years), personal history of fracture, alcohol
consumption, weight loss, lack of exercise and situations
of decreased bone strength, such as androgen suppres-
sion, rheumatoid arthritis, diabetes mellitus, hypothyr-
oidism, chronic obstructive pulmonary disease,
symptoms of gastrointestinal malabsorption, and cardio-
vascular disease [16]; also, exposure to certain drugs
other than typical corticosteroids, such as anti-androgen
therapy, thyroid therapy, hypolipidemic drugs (statins),
antidiabetic drugs (glytazones), and antacids (proton
pump inhibitors [17]). The evidence for some of these is
controversial.
There is consensus on the use of clinical risk factors
for fracture in combination with bone mineral density
(BMD) measurements in the evaluation and the deci-
sion-making process regarding OP patients. Reliable
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and women, such as the FRAX™ algorithm designed by
the WHO, are now available [18]. This tool has proved to
be very valuable to detect densitometric osteoporosis in a
Spanish population [19,20], and allows obtaining absolute
10-year probability of major or hip fracture by using clin-
ical risk factors for fracture associated or not associated
to bone density measurement by DXA. Recently, the eva-
luation of fracture risk factors other than those included
in the FRAX™ is being advised [21]. This study attempts
to update knowledge on this subject, with focus placed
on a Spanish male population.
Objectives
Primary objective
To determine the loss of health-related quality of life in
men with osteoporosis or osteoporotic fracture in a
Spanish population.
Secondary objective
To determine the relationship between questionnaire
clinical risk factors for osteoporotic fracture (age, body
mass index), personal and family history of fracture,
comorbidity, risk of falls, pharmacological treatments,
low bone mineral density) and health-related quality of
life in a male population.
Methods/Design
Design
This was an observational study of a random sample of
men included in a quota of primary care physicians
from the 4 provinces of Catalonia to evaluate HRQOL
in the scope of osteoporosis.
Study population
Urban environment, primary care.
Men ≥ 40 years of age with/without diagnosed OP and
with/without osteoporotic fracture who are asked by
their family doctor (either during consultation or by tel-
ephone and by the e-CAP software [22] used in primary
care centers attached to the Catalan Institute of Health)
to answer a questionnaire on risk factors for osteoporo-
tic fracture and on existing fractures, as well as a further
telephone questionnaire on HRQOL.
Sample size
Assuming a 0.35 deviation of EQ-5D, a difference in the
means of the variables between fractured and non-frac-
tured patients of 0.15 is detected in a sample of 280 indi-
viduals (140 fractured and 140 non-fractured individuals,
statistical significance set at 5% and power of 95%).
Sample screening
Random sample of men from the populations assigned
to the participating primary care physicians from the 4
provinces of Catalonia, age- and sex-matched to the
population of Catalonia.
Inclusion criteria
Male individuals born and living in Catalonia, of Cauca-
sian race, and aged ≥ 40 years and ≤ 90 years at the
time of inclusion in the study (FRAX™ is calculated in
populations aged 40-90 years). Men able to understand
and express themselves in the Spanish or Catalan lan-
guage, able to answer the questionnaire as written and
agreeing to participate in the study by signing an
informed consent form. Physically or mentally disabled
subjects whose representative agrees to answer the ques-
tionnaires and gives consent on behalf of the subject.
Exclusion criteria
Subjects aged < 40 years and/or > 90 years at the time
of sampling. Subjects with physical or mental difficulties
or limitations that prevent them from participating in
the study as scheduled or with relatives who refuse to
answer the questionnaires. Subjects with Paget’sd i s e a s e
or bone cancer. Subjects refusing to complete the ques-
tionnaires during the clinical interview or failing to give
their consent to answer the telephone questionnaire for
any reason. Subjects failing to provide a contact tele-
phone number, or failing to respond to 3 phone calls
made at different times.
Overview of outcome measurements
Data collection
The project will be initiated at primary care centers by
physicians specializing in Family and Community Medi-
cine. Field work will include completing a RFQ and
ascertaining the existence of fracture at the clinic or by
telephone (by the family doctor responsible for the par-
ticipating subject) once verbal consent has been
obtained and recorded. The participation of the different
primary care investigating physicians will be coordinated
and supervised by the primary care centers CAP Gir-
ona-2 and CAP Badía del Vallés, which will also gather
the information collected in the different provinces, with
data treatment performed by a statistician and a data-
base manager. Upon the collection of the above infor-
mation, the principal investigator of this study -also a
physician specializing in Family and Community Medi-
cine- will make phone calls from the CAP Girona-2 cen-
ter to administer the HRQOL questionnaires.
This study has been authorized by the CREC of the
Hospital Vall d’Hebron of Barcelona. Also, consent to
p a r t i c i p a t ei nt h es t u d ya n dt oa n s w e rt h eq u e s t i o n -
n a i r e s ,a sw e l la sf u t u r ec o n t a c t so ft h er e s e a r c ht e a m ,
will be gathered from electronic medical records.
Baseline variables and RFQs will be collected at the
time of inclusion (2011). Current variables will be
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ing individuals have been recorded (june 2011-december
2012).
Baseline variables
￿ Patient-related variables:
○ Demographic variables: date of birth (dd/mm/
yyyy).
○ Anthropometric variables: bodyweight (kg), height
(cm), body mass index (BMI) (kg/m
2).
○ Level of education: none/primary/secondary/higher
education.
○ Employment status: employed/unemployed/
retired/disabled.
￿ Clinical risk factors for fracture:
○ Family history of hip fracture (father/mother). Y/N
○ Medical history of diseases involving loss of bone
strength. Y/N
○ History of fragility fracture (defined as fall from
standing height or less). Y/N. Location and date will
be recorded. Axial skeleton fractures (ribs, dorsal
and lumbar vertebrae) and peripheral fractures
(wrist, femur and humerus) will be evaluated.
○ Smoking. Y/N
○ Alcohol risk intake (> 3 AU/week). Y/N
○ History of glucocorticoids intake for at least 3
months and doses ≥ 5 mg/day in the past 2 years: Y/N.
○ Medical history of osteoporotic medication. Y/N.
Name and number of months.
○ Number of falls over the past year. While different
ways to analyze falls have been found in the litera-
ture, the most frequently used one was selected in
o u rs t u d y ,i . e .a s k i n ga b o u tt h en u m b e ro ff a l l so v e r
the year before administering the questionnaire, and
whether any of these falls resulted in fractures.
▪ Use of walking cane: Y/N
▪ Needs help to stand up from a chair: Y/N
￿ Previous Bone Density Scan by Dual-energy X-ray
absorptiometry (DXA): Y/N. BMD measurement record-
ing if present in the medical record. These values will
be analyzed according to internationally accepted WHO
criteria of 1994 and ISCD recommendations. (Available
at: http://www.iscd.org/Visitors/positions/OfficialPosi-
tionsText.cfm).
￿ Percent values obtained by the FRAX™ calculation
tool regarding absolute risk of major osteoporotic frac-
ture (hip, humerus, forearm and clinical spine) and hip
fracture. The variables are gathered in the RFQ and cal-
culations are performed at the official website (http://
www.shef.ac.uk/FRAX). All results are expressed in
percentage (%) of absolute risk of sustaining a new
(major or hip) fracture during the following 10 years.
Individual calculations on a case-by-case basis are per-
formed by two separate investigators. The results of
each calculation are analyzed by another two investiga-
tors. The results are compared by another two investiga-
tors, and any difference found leads to risk recalculation
(triple evaluation of risk calculated by FRAX).
Follow up variables
HRQOL questionnaires.
￿ General (See annex 1: EQ-5D quality of life
questionnaire).
￿ OP-specific (See annex 2: ECO-16 quality of life
questionnaire).
Type of analysis
The characteristics of the studied population will be
described by univariate descriptive analysis with calcula-
tion of median, mean, standard deviation, maximum
and minimum values, and percentages for categorical
data. Bar charts and histograms will be used for graphi-
cal representation.
The association between qualitative variables will be
assessed by the Chi-square test.
The differences in the distribution of a quantitative
variable according to the categories defined for a bin-
ary qualitative character will be assessed by Student’s
t-test. If the conditions for using this test are not met,
the non-parametric Mann-Whitney’sUt e s tw i l lb e
used [23].
The differences in the distribution of a quantitative
variable according to the categories defined by a qualita-
tive variable with more than 2 categories will be
assessed by analysis of variance (ANOVA) or the
equivalent non-parametric test (Kruskal-Wallis) [23].
Bivariate comparisons between categorical variables
(Chi-square test) and between quantitative and categori-
cal variables (Student’s t-test) will be performed to
ascertain the age- and sex-related distribution of risk
factors associated with sustaining a fracture.
The validation of the results obtained by means of the
FRAX™ tool will be performed by way of the Hosmer-
Lemeshow test and by calculating the area under the
Receiver Operating Characteristic (ROC) curve (AUC).
The Hosmer-Lemeshow test [23] consists of dividing
our individuals in k groups (usually 10) depending on
their lower or higher fracture risk according to FRAX™,
and checking that each group actually presents with a
number of fractures that matches the FRAX™ predic-
tion. Few cases are expected in the first (lower risk)
group, with successive increases in the following groups.
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set at 95%. Analyses will be performed with SPSS statis-
tics software 16.0 or higher.
Personal data protection
The investigators guarantee and hold themselves
responsible for data confidentiality. All data are entered
into a computer database where patients are identified
by a code. A parallel database is created which includes
the particulars of each participant and the related code.
T h i sd a t a b a s ec a no n l yb ea c c e s s e db yt h eP r i n c i p a l
Investigator, the Coordinating Investigator and the
Computer Technician.
Discussion
The applicability and usefulness of HRQOL studies are
well documented in many countries. These studies allow
implementing cost-effective measures in cases of a given
disease and reducing the costly consequences derived
therefrom. This study attempts to provide objective data
on how quality of life is affected by the clinical aspects
involved in osteoporosis in a Spanish male population.
The studies so far conducted in men included small
populations. The purpose of this study is to evaluate a
larger population -representative of the general popula-
tion- and thus obtain generalizable results and data
likely to be useful in cost utility analyses conducted by
health authorities.
The publication in 2008 of the FRAX tool to calculate
10-year absolute probability of fragility fractures offers a
new approach to patients at higher risk of sustaining a
fracture. In the pilot test where the FRAX™ fracture
risk calculator was used in 100 real cases, errors
between 1-3% were detected in each case. The analysis
plan with the FRAX™ calculator will include double
analysis performed by several investigators blinded to
calculation results. Any and all differences will be evalu-
ated by a third investigator.
Our study has several strengths and limitations. The
HRQOL questionnaires selected are to be self-adminis-
tered, that is, completed by the patients themselves.
Because these questionnaires will be administered by
telephone by a well-documented, well-trained physician,
we hope to reduce the limitations specific to this data
collection system [24].
T h eE C O S - 1 6q u e s t i o n n a i r eh a sb e e nv a l i d a t e di n
women. In our opinion, however, this does not invali-
date the results of the study because no sex-specific
questions or answers were envisaged.
The sample selected is not based on a high fracture
risk group. Rather, it is composed of men in the general
population, and accordingly comparisons should not
lead to erroneous interpretations.
Data collection may involve biased information on
incident fractures, it being obtained according to the
patient’s account (no X-ray tests). Consequently, a small
percentage of (basically vertebral) silent fractures may
go undetected. Nevertheless, this is a questioner, inter-
nationally accepted means of ascertaining the incidence
of fractures in epidemiological studies, known as self-
reported related fractures. Bias correction will be
ensured by checking reported fractures against health-
care reports and X-rays, or by consulting health care
centers as applicable.
Appendices
Annex 1: EQ-5D QUALITY OF LIFE QUESTIONNAIRE
Under each heading, please tick the ONE box that best
describes your health TODAY.
Mobility
I have no problems in walking about ❏
I have slight problems in walking about ❏
I have moderate problems in walking about ❏
I have severe problems in walking about ❏
I am unable to walk about ❏
Self-Care
I have no problems washing or dressing myself ❏
I have slight problems washing or dressing myself ❏
I have moderate problems washing or dressing myself ❏
I have severe problems washing or dressing myself ❏
I am unable to wash or dress myself ❏
Usual activities (e.g. work, study, housework, family or
leisure activities)
I have no problems doing my usual activities ❏
I have slight problems doing my usual activities ❏
I have moderate problems doing my usual activities ❏
I have severe problems doing my usual activities ❏
I am unable to do my usual activities ❏
Pain/Discomfort
I have no pain or discomfort ❏
I have slight pain or discomfort ❏
I have moderate pain or discomfort ❏
I have severe pain or discomfort ❏
I have extreme pain or discomfort ❏
Anxiety/depression
I am not anxious or depressed ❏
I am slightly anxious or depressed ❏
I am moderately anxious or depressed ❏
I am severely anxious or depressed ❏
I am extremely anxious or depressed ❏
Annex 2: ECOS-16 QUALITY OF LIFE QUESTIONNAIRE
1. How often have you had back pain in the last
week?
☐ 1. I have had no back pain (proceed to question no 6)
☐ 2. 1 day
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☐ 4. 4-6 days
☐ 5. Every day
2. How severe was your back pain?
☐ 1. Mild
☐ 2. Annoying
☐ 3. Moderate
☐ 4. Severe
☐ 5. Intolerable
3. How much distress or discomfort have you had
due to pain from standing for a long time?
☐ 1. No discomfort or suffering
☐ 2. Slight discomfort or suffering
☐ 3. Moderate discomfort or suffering
☐ 4. Severe discomfort or suffering
☐ 5. Very severe discomfort or suffering
4. How much distress or discomfort have you had
due to pain from bending?
☐ 1. No discomfort or suffering
☐ 2. Slight discomfort or suffering
☐ 3. Moderate discomfort or suffering
☐ 4. Severe discomfort or suffering
☐ 5. Very severe discomfort or suffering
5. Has back pain disturbed your sleep in the last
seven days?
☐ 1. On no occasion
☐ 2. One night
☐ 3. Two nights
☐ 4. Three or four nights
☐ 5. Every night
6. How difficult has it been for you to carry out
household activities?
☐ 1. No difficulty
☐ 2. Slight difficulty
☐ 3. Moderate difficulty
☐ 4. Great difficulty
☐ 5. I was unable to do anything at all
7. Can you climb stairs to the next floor of a
house?
☐ 1. No difficulty
☐ 2. Slight difficulty
☐ 3. I had to rest at least once
☐ 4. I could only climb the stairs with help
☐ 5. I was unable to climb the stairs
8. Do you have problems with dressing?
☐ 1. No difficulty
☐ 2. I can dress myself with slight difficulty
☐ 3. I can dress myself with moderate difficulty
☐ 4. I sometimes need help to dress myself
☐ 5. I cannot dress myself unaided
9. How difficult has it been for you to bend?
☐ 1. No difficulty
☐ 2. Slight difficulty
☐ 3. Moderate difficulty
☐ 4. Great difficulty
☐ 5. I am unable to bend down
10. How much has your walking been limited?
☐ 1. Not limited
☐ 2. Slightly limited
☐ 3. Moderately limited
☐ 4. Very limited
☐ 5. I am unable to walk
11. How difficult has it been for you to visit friends
or relatives?
☐ 1. No difficulty
☐ 2. Slight difficulty
☐ 3. Moderate difficulty
☐ 4. Great difficulty
☐ 5. I have been unable to visit friends or relatives
12. Have you felt downhearted?
☐ 1. No
☐ 2. Rarely
☐ 3. Sometimes
☐ 4. Often
☐ 5. Always
13. Are you hopeful about your future?
☐ 1. Always
☐ 2. Often
☐ 3. Sometimes
☐ 4. Rarely
☐ 5. No
14. Have you felt frustrated?
☐ 1. No
☐ 2. Rarely
☐ 3. Sometimes
☐ 4. Often
☐ 5. Always
15. Have you been afraid of falling?
☐ 1. No
☐ 2. Rarely
☐ 3. Sometimes
☐ 4. Often
☐ 5. Always
16. Have you been afraid of sustaining a fracture?
☐ 1. No
☐ 2. Rarely
☐ 3. Sometimes
☐ 4. Often
☐ 5. Always
List of abbreviations
RFQ: Risk Factor Questionnaire; HRQOL: Health-Related Quality Of Life; DXA:
Dual-Energy X-Ray Absorptiometry; BMD: Bone Mineral Density; EQ-5D:
EuroQol-5D; EVOS: European Vertebral Osteoporosis Fracture Study; FRAX™:
Fracture Risk Assessment tool; BMI: Body Mass Index; ISCD: International
Society for Clinical Densitometry; OP: Osteoporosis; Qualeffo: Quality of Life
Questionnaire of the European Foundation for Osteoporosis; Y: Yes; N: No;
AU: Alcohol units.
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